1
|
Di Gregorio E, Rosa E, Ferrauto G, Diaferia C, Gallo E, Accardo A, Terreno E. Development of cationic peptide-based hydrogels loaded with iopamidol for CEST-MRI detection. J Mater Chem B 2023; 11:7435-7441. [PMID: 37435712 DOI: 10.1039/d3tb00187c] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/13/2023]
Abstract
Peptide-based hydrogels have been recently investigated as materials for biomedical applications like tissue engineering and delivery of drugs and imaging agents. Among the synthetic peptide hydrogelators, the cationic hexapeptides Ac-K1 and Ac-K2 were proposed as scaffolds for bioprinting applications. Here, we report the formulation of Ac-K1 and Ac-K2 hydrogels loaded with iopamidol, an iodinated contrast agent clinically approved for X-ray computed tomography, and more recently identified as an efficient CEST-MRI probe. Iopamidol-loaded hydrogels were soft, injectable and non-toxic both in vitro (on three tumor cell lines: GL261, TS/A and 3T3-NIH) and in vivo (in Balb/c mice inoculated with TS/A breast cancer cells). The in vitro CEST-MRI study evidenced the typical features of the CEST pattern of iopamidol, with a CEST contrast higher than 50%. Due to their injectability and good ability to retain the contrast agent, the herein investigated systems can be considered as promising candidates for the development of smart MRI detectable hydrogels.
Collapse
Affiliation(s)
- Enza Di Gregorio
- Molecular and Preclinical Imaging Center, Department of Molecular Biotechnology and Health Sciences, University of Turin, Via Nizza 52, Turin, Italy.
| | - Elisabetta Rosa
- Department of Pharmacy and Interuniversity Research Centre on Bioactive Peptides (CIRPeB) "Carlo Pedone", University of Naples "Federico II", Via D. Montesano 49, Naples 80131, Italy
| | - Giuseppe Ferrauto
- Molecular and Preclinical Imaging Center, Department of Molecular Biotechnology and Health Sciences, University of Turin, Via Nizza 52, Turin, Italy.
| | - Carlo Diaferia
- Department of Pharmacy and Interuniversity Research Centre on Bioactive Peptides (CIRPeB) "Carlo Pedone", University of Naples "Federico II", Via D. Montesano 49, Naples 80131, Italy
| | - Enrico Gallo
- IRCCS Synlab SDN, Via Gianturco 113, Naples, 80143, Italy
| | - Antonella Accardo
- Department of Pharmacy and Interuniversity Research Centre on Bioactive Peptides (CIRPeB) "Carlo Pedone", University of Naples "Federico II", Via D. Montesano 49, Naples 80131, Italy
| | - Enzo Terreno
- Molecular and Preclinical Imaging Center, Department of Molecular Biotechnology and Health Sciences, University of Turin, Via Nizza 52, Turin, Italy.
| |
Collapse
|
2
|
Kurz FT, Schlemmer HP. Imaging in translational cancer research. Cancer Biol Med 2022; 19:j.issn.2095-3941.2022.0677. [PMID: 36476372 PMCID: PMC9724222 DOI: 10.20892/j.issn.2095-3941.2022.0677] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2022] [Accepted: 11/11/2022] [Indexed: 12/12/2022] Open
Abstract
This review is aimed at presenting some of the recent developments in translational cancer imaging research, with a focus on novel, recently established, or soon to be established cross-sectional imaging techniques for computed tomography (CT), magnetic resonance imaging (MRI), and positron-emission tomography (PET) imaging, including computational investigations based on machine-learning techniques.
Collapse
Affiliation(s)
- Felix T. Kurz
- Department of Radiology, German Cancer Research Center, Heidelberg 69120, Germany
| | | |
Collapse
|
3
|
Boyd PS, Breitling J, Korzowski A, Zaiss M, Franke VL, Mueller-Decker K, Glinka A, Ladd ME, Bachert P, Goerke S. Mapping intracellular pH in tumors using amide and guanidyl CEST-MRI at 9.4 T. Magn Reson Med 2021; 87:2436-2452. [PMID: 34958684 DOI: 10.1002/mrm.29133] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2021] [Revised: 11/26/2021] [Accepted: 12/07/2021] [Indexed: 12/11/2022]
Abstract
PURPOSE In principle, non-invasive mapping of the intracellular pH (pHi ) in vivo is possible using endogenous chemical exchange saturation transfer (CEST)-MRI of the amide and guanidyl signals. However, the application for cancer imaging is still impeded, as current state-of-the-art approaches do not allow for simultaneous compensation of concomitant effects that vary within tumors. In this study, we present a novel method for absolute pHi mapping using endogenous CEST-MRI, which simultaneously compensates for concentration changes, superimposing CEST signals, magnetization transfer contrast, and spillover dilution. THEORY AND METHODS Compensation of the concomitant effects was achieved by a ratiometric approach (i.e. the ratio of one CEST signal at different B1 ) in combination with the relaxation-compensated inverse magnetization transfer ratio MTRRex and a separate first-order polynomial-Lorentzian fit of the amide and guanidyl signals at 9.4 T. Calibration of pH values was accomplished using in vivo-like model suspensions from porcine brain lysates. Applicability of the presented method in vivo was demonstrated in n = 19 tumor-bearing mice. RESULTS In porcine brain lysates, measurement of pH was feasible over a broad range of physiologically relevant pH values of 6.2 to 8.0, while being independent of changes in concentration. A median pHi of approximately 7.2 was found in the lesions of 19 tumor-bearing mice. CONCLUSION The presented method enables non-invasive mapping of absolute pHi values in tumors using CEST-MRI, which was so far prevented by concomitant effects. Consequently, pre-clinical studies on pHi changes in tumors are possible allowing the assessment of pHi in vivo as a biomarker for cancer diagnosis or treatment monitoring.
Collapse
Affiliation(s)
- Philip S Boyd
- Division of Medical Physics in Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.,Faculty of Physics and Astronomy, University of Heidelberg, Heidelberg, Germany
| | - Johannes Breitling
- Division of Medical Physics in Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Andreas Korzowski
- Division of Medical Physics in Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Moritz Zaiss
- Division of Neuroradiology in Radiological Institute, University Hospital of Erlangen, Erlangen, Germany
| | - Vanessa L Franke
- Division of Medical Physics in Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.,Faculty of Physics and Astronomy, University of Heidelberg, Heidelberg, Germany
| | - Karin Mueller-Decker
- Core Facility Tumor Models (Center for Preclinical Research), German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Andrey Glinka
- Division of Molecular Embryology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Mark E Ladd
- Division of Medical Physics in Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.,Faculty of Physics and Astronomy, University of Heidelberg, Heidelberg, Germany.,Faculty of Medicine, University of Heidelberg, Heidelberg, Germany
| | - Peter Bachert
- Division of Medical Physics in Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.,Faculty of Physics and Astronomy, University of Heidelberg, Heidelberg, Germany
| | - Steffen Goerke
- Division of Medical Physics in Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| |
Collapse
|
4
|
Hyder F, Coman D. Imaging Extracellular Acidification and Immune Activation in Cancer. CURRENT OPINION IN BIOMEDICAL ENGINEERING 2021; 18. [PMID: 33997581 DOI: 10.1016/j.cobme.2021.100278] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Metabolism reveals pathways by which cells, in healthy and disease tissues, use nutrients to fuel their function and (re)growth. However, gene-centric views have dominated cancer hallmarks, relegating metabolic reprogramming that all cells in the tumor niche undergo as an incidental phenomenon. Aerobic glycolysis in cancer is well known, but recent evidence suggests that diverse symbolic traits of cancer cells are derived from oncogene-directed metabolism required for their sustenance and evolution. Cells in the tumor milieu actively metabolize different nutrients, but proficiently secrete acidic by-products using diverse mechanisms to create a hostile ecosystem for host cells, and where local immune cells suffer collateral damage. Since metabolic interactions between cancer and immune cells hold promise for future cancer therapies, here we focus on translational magnetic resonance methods enabling in vivo and simultaneous detection of tumor habitat acidification and immune activation - innovations for monitoring personalized treatments.
Collapse
Affiliation(s)
- Fahmeed Hyder
- Department of Biomedical Engineering, Yale University, New Haven, CT, USA
- Department of Radiology & Biomedical Imaging, Yale University, New Haven, CT, USA
- Magnetic Resonance Research Center (MRRC), Yale University, New Haven, CT, USA
- Quantitative Neuroimaging with Magnetic Resonance (QNMR) Research Program, Yale University, New Haven, CT, USA
| | - Daniel Coman
- Department of Radiology & Biomedical Imaging, Yale University, New Haven, CT, USA
- Magnetic Resonance Research Center (MRRC), Yale University, New Haven, CT, USA
| |
Collapse
|